肿瘤细胞治疗研究
英文原题：Overall review of curative impact and barriers of CAR-T cells in osteosarcoma.
骨肉瘤（OS）是一种罕见的癌症，也是儿童和青少年中的原发性骨恶性肿瘤。
骨肉瘤（OS）是一种罕见癌症，也是儿童和青少年的原发性骨恶性肿瘤。目前治疗包括手术、化疗和截肢，因此亟需新的治疗策略以显著改变治疗格局。近年来，CAR-T 细胞疗法受到广泛关注，在治疗中显示出良好前景，且部分患者输注后出现的轻微副作用可通过现有治疗缓解。不过，也有患者发生细胞因子释放综合征（CRS）。此外，研究者仍需解决限制和抑制 T 细胞功能的问题。为最大限度发挥 CAR-T 疗法的治疗获益，有研究提出联合治疗可能更有助于克服现有障碍并尽可能减少副作用。本综述总结了这些问题和障碍，并回顾了部分评估 CAR-T 治疗骨肉瘤患者的研究结果。
Osteosarcoma (OS) is a rare form of cancer and primary bone malignancy in children and adolescents. Current therapies include surgery, chemotherapy, and amputation. Therefore, a new therapeutic strategy is needed to dramatically change cancer treatment. Recently, chimeric antigen receptor T cells (CAR-T cells) have been of considerable interest as it has provided auspicious results and patients suffering from low side effects after injection that resolve with current therapy. However, there are reports that cytokine release storm (CRS) can be observed in some patients. In addition, as researchers have faced problems that limit and suppress T cells, further studies are required to resolve these problems. In addition, to maximize the therapeutic benefit of CAR-T cell therapy, researchers have suggested that combination therapy could be better used to treat cancer by overcoming any problems and reducing side effects as much as possible. This review summarizes these problems, barriers, and the results of some studies on the evaluation of CAR-T cells in patients with osteosarcoma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
